The estimated Net Worth of Keith Michael Gottesdiener is at least $13.4 Million dollars as of 9 March 2020. Keith Gottesdiener owns over 3,408 units of Intercept Pharmaceuticals Inc stock worth over $10,606,750 and over the last 8 years he sold ICPT stock worth over $2,479,050. In addition, he makes $316,356 as Independent Director at Intercept Pharmaceuticals Inc.
Keith has made over 16 trades of the Intercept Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 3,408 units of ICPT stock worth $20,925 on 9 March 2020.
The largest trade he's ever made was exercising 33,072 units of Intercept Pharmaceuticals Inc stock on 8 January 2020 worth over $151,800. On average, Keith trades about 4,910 units every 25 days since 2016. As of 9 March 2020 he still owns at least 558,250 units of Intercept Pharmaceuticals Inc stock.
You can see the complete history of Keith Gottesdiener stock trades at the bottom of the page.
Dr. Keith M. Gottesdiener serves as Independent Director of the Company.D. is an Independent Director of the Company. Dr. Gottesdiener has been the Chief Executive Officer and a director of Rhythm Pharmaceuticals, Inc., a biopharmaceutical company. Dr. Gottesdiener joined Rhythm after 16 years at Merck Research Laboratories, where he held positions of increasing responsibility, including serving as a leader of Merck’s late clinical development organization from 2006 to 2011 and leading Merck’s early clinical development across all therapeutic areas from 2001 through early 2006. Dr. Gottesdiener oversaw the development of Merck’s infectious diseases and vaccine products through pivotal trials, registration, and life cycle management, including GardasilTM (HPV Vaccine), RotateqTM (rotavirus vaccine), ZostavaxTM (zoster vaccine) and IsentressTM (HIV integrase inhibitor), among others. In 2008, Dr. Gottesdiener was appointed Late Stage Therapeutic Group Leader, and in that role led Merck’s late-stage clinical development efforts (from Phase 2 through patent expiry) across all therapeutic areas. After Merck’s merger with Schering-Plough Corporation in 2009, he continued as Co-Head of Late Development. Dr. Gottesdiener received his B.A. from Harvard College and his M.D. from the University of Pennsylvania. He completed his residency and fellowship at the Brigham and Women’s Hospital-Beth Israel Medical Center-Dana Farber Cancer Institute Children’s Hospital programs. After his fellowship, Dr. Gottesdiener did postdoctoral research in the laboratory of Dr. Jack Strominger at Dana Farber Cancer Institute working on the molecular immunology of the T-cell receptor. In 1986, he joined the faculty as an assistant professor at Columbia University, started an independent research laboratory with NIH RO-1 funding, focusing on gene transcription, and was Associate Clinical Professor of Medicine at the time he left to join Merck in 1995
As the Independent Director of Intercept Pharmaceuticals Inc, the total compensation of Keith Gottesdiener at Intercept Pharmaceuticals Inc is $316,356. There are 17 executives at Intercept Pharmaceuticals Inc getting paid more, with Mark Pruzanski having the highest compensation of $6,615,780.
Keith Gottesdiener is 66, he's been the Independent Director of Intercept Pharmaceuticals Inc since 2016. There are no older and 24 younger executives at Intercept Pharmaceuticals Inc.
Keith's mailing address filed with the SEC is C/O INTERCEPT PHARMACEUTICALS, INC., 305 MADISON AVENUE, MORRISTOWN, NJ, 07960.
Over the last 12 years, insiders at Intercept Pharmaceuticals Inc have traded over $1,530,243,701 worth of Intercept Pharmaceuticals Inc stock and bought 2,408,920 units worth $77,118,364 . The most active insiders traders include Srinivas Akkaraju, Jonathan Silverstein, and Francesco Micheli. On average, Intercept Pharmaceuticals Inc executives and independent directors trade stock every 10 days with the average trade being worth of $1,114,673. The most recent stock trade was executed by Srinivas Akkaraju on 10 March 2021, trading 237,000 units of ICPT stock currently worth $5,017,290.
we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.
Intercept Pharmaceuticals Inc executives and other stock owners filed with the SEC include: